- Home
- AMRN vs LRMR Comparison
AMRN vs LRMR Comparison
Compare AMRN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- LRMR
- Stock Information
- Founded
- AMRN 1989
- LRMR N/A
- Country
- AMRN Ireland
- LRMR United States
- Employees
- AMRN N/A
- LRMR N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- LRMR Health Care
- Exchange
- AMRN Nasdaq
- LRMR Nasdaq
- Market Cap
- AMRN 189.2M
- LRMR 183.8M
- IPO Year
- AMRN 1993
- LRMR N/A
- Fundamental
- Price
- AMRN $9.11
- LRMR $1.91
- Analyst Decision
- AMRN Sell
- LRMR Strong Buy
- Analyst Count
- AMRN 2
- LRMR 9
- Target Price
- AMRN $7.00
- LRMR $19.00
- AVG Volume (30 Days)
- AMRN 103.6K
- LRMR 1.0M
- Earning Date
- AMRN 04-30-2025
- LRMR 05-08-2025
- Dividend Yield
- AMRN N/A
- LRMR N/A
- EPS Growth
- AMRN N/A
- LRMR N/A
- EPS
- AMRN N/A
- LRMR N/A
- Revenue
- AMRN $228,614,000.00
- LRMR N/A
- Revenue This Year
- AMRN N/A
- LRMR N/A
- Revenue Next Year
- AMRN $5.18
- LRMR N/A
- P/E Ratio
- AMRN N/A
- LRMR N/A
- Revenue Growth
- AMRN N/A
- LRMR N/A
- 52 Week Low
- AMRN $7.00
- LRMR $1.61
- 52 Week High
- AMRN $20.60
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- AMRN 48.45
- LRMR 39.39
- Support Level
- AMRN $8.32
- LRMR $1.76
- Resistance Level
- AMRN $10.06
- LRMR $1.91
- Average True Range (ATR)
- AMRN 0.87
- LRMR 0.17
- MACD
- AMRN 0.15
- LRMR 0.03
- Stochastic Oscillator
- AMRN 60.40
- LRMR 46.15
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.